The estimated Net Worth of Raymond Winquist is at least $38.7 Тысяча dollars as of 18 August 2017. Raymond Winquist owns over 1,000 units of Xenon Pharmaceuticals Inc stock worth over $38,650 and over the last 9 years Raymond sold XENE stock worth over $0.
Raymond has made over 1 trades of the Xenon Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Raymond bought 1,000 units of XENE stock worth $3,000 on 18 August 2017.
The largest trade Raymond's ever made was buying 1,000 units of Xenon Pharmaceuticals Inc stock on 18 August 2017 worth over $3,000. On average, Raymond trades about 250 units every 0 days since 2016. As of 18 August 2017 Raymond still owns at least 1,000 units of Xenon Pharmaceuticals Inc stock.
You can see the complete history of Raymond Winquist stock trades at the bottom of the page.
Raymond's mailing address filed with the SEC is C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY, A1, V5G 4W8.
Over the last 10 years, insiders at Xenon Pharmaceuticals Inc have traded over $12,977,011 worth of Xenon Pharmaceuticals Inc stock and bought 724,015 units worth $2,649,316 . The most active insiders traders include Patrick Machado, Partners L P/Ilbiotechnolog... и Justin D. Gover. On average, Xenon Pharmaceuticals Inc executives and independent directors trade stock every 31 days with the average trade being worth of $818,878. The most recent stock trade was executed by Elizabeth A. Garofalo on 8 March 2024, trading 3,500 units of XENE stock currently worth $64,960.
xenon® (nasdaq: xene) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as extreme genetics. our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. we apply our expertise to predict which phenotypes are caused by single-gene defects. by identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.
Xenon Pharmaceuticals Inc executives and other stock owners filed with the SEC include: